News

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Raanana, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the successful preliminary safety study for a formulation of its PL-14 Allergy Blocker, marking a significant advancement in the product's development path.

04/25/2025

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Raanana, Israel, April 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that on April 8, 2025, the Company received a written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company's closing bid price for its ordinary shares was below $1.00 per share for the last 30 consecutive business days.

04/11/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

What is Polyrizon Ltd.'s stock price?

The price of Polyrizon Ltd. (PLRZ) is 0.5954 and it was updated on 2025-05-08 13:00:21.

Is Polyrizon Ltd. (PLRZ) overvalued or undervalued?

Currently Polyrizon Ltd. (PLRZ) is in undervalued.

News

From:

To:

News
Polyrizon Engages Leading Branding Firm for Strategic Brand Development Raanana, Israel, April 02, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company specializing in innovative intranasal hydrogels, today announced that it has entered into an agreement with a globally recognized branding and trademark consultancy firm, renowned for working with leading pharmaceutical and medical device companies worldwide. Wed, Apr. 02, 2025
Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement RAANANA, ISRAEL, April 01, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a biotech company specializing in innovative intranasal hydrogels, today announced the closing of its previously announce private placement of approximately $17.0 million of Ordinary Shares and/or pre-funded and investor warrants at a price of $0.48 per Ordinary Unit. Tue, Apr. 01, 2025
Polyrizon Ltd. Announces $17.0 Million Private Placement RAANANA, ISRAEL, March 31, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a biotech company specializing in innovative intranasal hydrogels, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of approximately $17.0 million of Ordinary Shares and/or pre-funded and investor warrants at a price of $0.48 per Ordinary Unit. Mon, Mar. 31, 2025
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting Studies to assess efficacy, safety, user experience, and nasal residence time as Company prepares for regulatory path forward Thu, Mar. 27, 2025
Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment Raanana, Israel, March 25, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the initiation of preclinical studies for intranasal Benzodiazepines (BZDs), a first-line treatment for acute repetitive seizures (ARS) and status epilepticus, using its proprietary drug delivery platform. Tue, Mar. 25, 2025

SEC Filings

SEC Filings
Polyrizon Ltd. (PLRZ) - 6-K - Current report SEC Filings 05/01/2025
Polyrizon Ltd. (PLRZ) - F-1 SEC Filings 04/30/2025
Polyrizon Ltd. (PLRZ) - 6-K - Current report SEC Filings 04/25/2025
Polyrizon Ltd. (PLRZ) - 6-K - Current report SEC Filings 04/17/2025
Polyrizon Ltd. (PLRZ) - 6-K - Current report SEC Filings 04/02/2025
Polyrizon Ltd. (PLRZ) - 6-K - Current report SEC Filings 04/01/2025
Polyrizon Ltd. (PLRZ) - 6-K - Current report SEC Filings 03/27/2025
Polyrizon Ltd. (PLRZ) - 6-K - Current report SEC Filings 03/25/2025
Polyrizon Ltd. (PLRZ) - EFFECT SEC Filings 03/19/2025
Polyrizon Ltd. (PLRZ) - 6-K - Current report SEC Filings 03/14/2025
Polyrizon Ltd. (PLRZ) - 6-K - Current report SEC Filings 03/13/2025
Polyrizon Ltd. (PLRZ) - POS AM SEC Filings 03/11/2025
Polyrizon Ltd. (PLRZ) - 20-F SEC Filings 03/11/2025
Polyrizon Ltd. (PLRZ) - 6-K - Current report SEC Filings 03/10/2025
Polyrizon Ltd. (PLRZ) - SCHEDULE 13G SEC Filings 03/05/2025
Polyrizon Ltd. (PLRZ) - 6-K - Current report SEC Filings 01/30/2025
Polyrizon Ltd. (PLRZ) - 6-K - Current report SEC Filings 01/23/2025
Polyrizon Ltd. (PLRZ) - S-8 SEC Filings 01/22/2025
Polyrizon Ltd. (PLRZ) - 6-K - Current report SEC Filings 01/21/2025
Polyrizon Ltd. (PLRZ) - EFFECT SEC Filings 01/16/2025
Polyrizon Ltd. (PLRZ) - CORRESP SEC Filings 01/13/2025
Polyrizon Ltd. (PLRZ) - F-1/A SEC Filings 01/10/2025
Polyrizon Ltd. (PLRZ) - UPLOAD SEC Filings 01/06/2025
Polyrizon Ltd. (PLRZ) - F-1 SEC Filings 12/30/2024
Polyrizon Ltd. (PLRZ) - 6-K - Current report SEC Filings 12/30/2024
Polyrizon Ltd. (PLRZ) - 6-K - Current report SEC Filings 12/19/2024
Polyrizon Ltd. (PLRZ) - 6-K - Current report SEC Filings 12/13/2024
Polyrizon Ltd. (PLRZ) - 6-K - Current report SEC Filings 12/02/2024
Polyrizon Ltd. (PLRZ) - 6-K - Current report SEC Filings 10/30/2024
Polyrizon Ltd. (PLRZ) - 424B4 SEC Filings 10/30/2024
Polyrizon Ltd. (PLRZ) - EFFECT SEC Filings 10/29/2024
Polyrizon Ltd. (PLRZ) - SEC STAFF LETTER SEC Filings 10/28/2024
Polyrizon Ltd. (PLRZ) - CERT SEC Filings 10/28/2024
Polyrizon Ltd. (PLRZ) - CORRESP SEC Filings 10/25/2024
Polyrizon Ltd. (PLRZ) - CORRESP SEC Filings 10/22/2024
Polyrizon Ltd. (PLRZ) - 8-A12B SEC Filings 10/21/2024
Polyrizon Ltd. (PLRZ) - CORRESP SEC Filings 10/18/2024
Polyrizon Ltd. (PLRZ) - F-1/A SEC Filings 10/02/2024
Polyrizon Ltd. (PLRZ) - SEC STAFF LETTER SEC Filings 09/30/2024
Polyrizon Ltd. (PLRZ) - CORRESP SEC Filings 09/30/2024
Polyrizon Ltd. (PLRZ) - CORRESP SEC Filings 09/26/2024
Polyrizon Ltd. (PLRZ) - F-1/A SEC Filings 09/25/2024
Polyrizon Ltd. (PLRZ) - F-1/A SEC Filings 09/23/2024
Polyrizon Ltd. (PLRZ) - CORRESP SEC Filings 09/23/2024
Polyrizon Ltd. (PLRZ) - UPLOAD SEC Filings 09/20/2024
Polyrizon Ltd. (PLRZ) - F-1/A SEC Filings 09/16/2024
Polyrizon Ltd. (PLRZ) - CORRESP SEC Filings 09/16/2024
Polyrizon Ltd. (PLRZ) - UPLOAD SEC Filings 09/13/2024
Polyrizon Ltd. (PLRZ) - F-1/A SEC Filings 09/09/2024
Polyrizon Ltd. (PLRZ) - F-1/A SEC Filings 09/04/2024
Polyrizon Ltd. (PLRZ) - CORRESP SEC Filings 09/03/2024
Polyrizon Ltd. (PLRZ) - UPLOAD SEC Filings 08/30/2024
Polyrizon Ltd. (PLRZ) - F-1/A SEC Filings 08/14/2024
Polyrizon Ltd. (PLRZ) - CORRESP SEC Filings 08/14/2024
Polyrizon Ltd. (PLRZ) - UPLOAD SEC Filings 06/14/2024
Polyrizon Ltd. (PLRZ) - F-1/A SEC Filings 05/20/2024
Polyrizon Ltd. (PLRZ) - RW WD SEC Filings 04/11/2024
Polyrizon Ltd. (PLRZ) - RW SEC Filings 03/28/2024
Polyrizon Ltd. (PLRZ) - UPLOAD SEC Filings 02/21/2024
Polyrizon Ltd. (PLRZ) - CORRESP SEC Filings 02/27/2023
Polyrizon Ltd. (PLRZ) - UPLOAD SEC Filings 02/16/2023
Polyrizon Ltd. (PLRZ) - F-1/A SEC Filings 02/03/2023
Polyrizon Ltd. (PLRZ) - CORRESP SEC Filings 02/03/2023
Polyrizon Ltd. (PLRZ) - UPLOAD SEC Filings 01/23/2023
Polyrizon Ltd. (PLRZ) - F-1/A SEC Filings 01/10/2023
Polyrizon Ltd. (PLRZ) - CORRESP SEC Filings 01/10/2023
Polyrizon Ltd. (PLRZ) - UPLOAD SEC Filings 12/23/2022
Polyrizon Ltd. (PLRZ) - F-1/A SEC Filings 12/19/2022
Polyrizon Ltd. (PLRZ) - CORRESP SEC Filings 12/19/2022
Polyrizon Ltd. (PLRZ) - UPLOAD SEC Filings 10/21/2022
Polyrizon Ltd. (PLRZ) - F-1/A SEC Filings 10/07/2022
Polyrizon Ltd. (PLRZ) - CORRESP SEC Filings 10/06/2022
Polyrizon Ltd. (PLRZ) - UPLOAD SEC Filings 08/17/2022
Polyrizon Ltd. (PLRZ) - F-1 SEC Filings 08/10/2022
Polyrizon Ltd. (PLRZ) - CORRESP SEC Filings 08/10/2022
Polyrizon Ltd. (PLRZ) - UPLOAD SEC Filings 06/02/2022
Polyrizon Ltd. (PLRZ) - DRSLTR SEC Filings 05/27/2022
Polyrizon Ltd. (PLRZ) - DRS/A SEC Filings 05/27/2022
Polyrizon Ltd. (PLRZ) - UPLOAD SEC Filings 05/17/2022
Polyrizon Ltd. (PLRZ) - DRSLTR SEC Filings 05/04/2022
Polyrizon Ltd. (PLRZ) - DRS/A SEC Filings 05/04/2022
Polyrizon Ltd. (PLRZ) - UPLOAD SEC Filings 04/19/2022
Polyrizon Ltd. (PLRZ) - DRSLTR SEC Filings 04/14/2022
Polyrizon Ltd. (PLRZ) - DRS/A SEC Filings 04/14/2022
Polyrizon Ltd. (PLRZ) - UPLOAD SEC Filings 03/10/2022
Polyrizon Ltd. (PLRZ) - DRSLTR SEC Filings 02/22/2022
Polyrizon Ltd. (PLRZ) - DRS/A SEC Filings 02/22/2022
Polyrizon Ltd. (PLRZ) - UPLOAD SEC Filings 02/07/2022
Polyrizon Ltd. (PLRZ) - DRS SEC Filings 01/10/2022

Press Releases

StockPrice Release
Polyrizon reports successful safety study of a formulation of pl-14 allergy blocker in human nasal tissue model 04/25/2025
Polyrizon receives nasdaq notification regarding minimum bid requirements 04/11/2025
Polyrizon engages leading branding firm for strategic brand development 04/02/2025
Polyrizon ltd. announces closing of $17.0 million private placement 04/01/2025
Polyrizon ltd. announces $17.0 million private placement 03/31/2025
Polyrizon structures clinical strategy for its allergy blocker ahead of fda pre-submission meeting 03/27/2025
Polyrizon expands drug delivery innovation with preclinical studies for epilepsy rescue treatment 03/25/2025
Polyrizon signs non– binding loi to expand its innovative intranasal drug delivery platform for psychedelic-based treatments 03/14/2025
Polyrizon launches preclinical studies for intranasal naloxone to combat opioid overdose using cutting-edge platform 03/13/2025
Polyrizon ltd. files annual report on form 20-f for the fiscal year ended december 31, 2024 03/11/2025
Polyrizon initiates preclinical studies for intranasal naloxone targeting opioid overdose based on its innovative t&t platform 03/10/2025
Polyrizon announces filing of divisional patent application for its innovative trap & target™ (t&t) intranasal drug delivery platform 01/30/2025
Polyrizon commences gmp manufacturing preliminary process for its pl-14 allergy blocker in preparation for planned 2025 clinical trial 01/23/2025
Polyrizon announces publication of u.s. national patent application for its innovative hydrogel nasal technologies 12/30/2024
Polyrizon appoints dr. michal meir as senior director of regulatory and clinical affairs 12/19/2024
Polyrizon's moving forward with expected 2025 clinical trial - entered manufacturing agreement for its pl-14 allergy blocker 12/18/2024
Polyrizon announces appointment of vp of regulatory affairs and quality assurance 12/13/2024
Polyrizon enters into gmp manufacturing agreement for ctm supply of its pl-14 allergy blocker in preparation for planned 2025 clinical trial 12/02/2024
Aegis capital corp. acted as sole bookrunner on a $4.2 million (ipo) initial public offering for polyrizon ltd. (nasdaq: plrz) 10/30/2024
Polyrizon announces closing of $4.2 million initial public offering 10/30/2024
Polyrizon announces pricing of $4.2 million initial public offering and listing on the nasdaq capital market under new ticker “plrz” 10/28/2024

More Headlines

News
Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments Raanana, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that it has signed a non-binding Letter of Intent (LOI) with a biotech company focused on psychedelic-derived therapeutics (“the psychedelic company”), to develop a novel intranasal formulation for psychedelic-based treatment applications. 03/14/2025
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform Raanana, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, previously announced the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment. 03/13/2025
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 Raanana, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (the "SEC"). 03/11/2025
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform Raanana, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment. 03/10/2025
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform Raanana, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a divisional patent application with the Israel Patent Office for its Trap & Target (T&T) platform technology. This application focuses exclusively on protecting the Company's advanced intranasal drug delivery system, which is designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues and aligns with the Company's recently announced U.S. patent application which encompasses key aspects of Polyrizon's two core platform technologies: Capture and Contain (C&C™), a nasal blocker technology, and Trap and Target (T&T™), designed for advanced nasal drug delivery. 01/30/2025
Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial Eurofins CDMO Amatsiaquitaine S.A.S., the GMP manufacturer, to support Polyrizon in future commercialization efforts Raanana, Israel, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. 01/23/2025
Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies Raanana, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the publication of a national phase patent application by the United States Patent and Trademark Office (“USPTO”). The patent application encompasses key aspects of Polyrizon's two core platform technologies: Capture and Contain (C&C™), a nasal blocker technology, and Trap and Target (T&T™), designed for advanced nasal drug delivery. Both technologies represent Polyrizon's commitment to creating innovative solutions for protecting and treating via the nasal cavity. 12/30/2024
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announce today the appointment of Dr. Michal Meir, Senior Consultant at MedTech SME Ltd., as Senior Director of Regulatory and Clinical Affairs. The appointment was made as part of the Company's preparations towards its clinical trial for PL-14 that is expected to commence in 2025. Dr. Meir brings over a decade of experience in the medical device and pharmaceutical industries, with a proven track record in regulatory strategy, clinical affairs management and product development. 12/19/2024
Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer has large-scale commercial production capabilities, to support Polyrizon in future commercialization efforts 12/18/2024
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today the appointment of Asaf Azulay, the Managing Director of Eurofins' Li-Med team, to its leadership as its VP of Regulatory Affairs and Quality Assurance (RA/QA). This strategic appointment reflects Polyrizon's ongoing commitment to maintaining the highest industry standards as it advances its pipeline of cutting-edge solutions. 12/13/2024
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer has large-scale commercial production capabilities, to support Polyrizon in future commercialization efforts 12/02/2024
Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ) NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Aegis Capital Corp. acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ:PLRZ). 10/30/2024
Polyrizon Announces Closing of $4.2 Million Initial Public Offering Raanana, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in the development of innovative medical device hydrogels, today announced the closing of its underwritten initial public offering of 958,903 units at a combined public offering price of $4.38 per unit, with each unit each consisting of one ordinary share and three warrants to purchase one ordinary share per warrant, with an initial exercise price of $4.38 per share. Aggregate gross proceeds were $4.2 million, prior to deducting underwriting discounts and offering expenses. 10/30/2024
Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ” Raanana, Israel, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in the development of innovative medical device hydrogels, today announced the pricing of its underwritten initial public offering of 958,903 units at a combined public offering price of $4.38 per unit, with each unit each consisting of one ordinary share and three warrants to purchase one ordinary share per warrant, with an initial exercise price of $4.38 per share. Aggregate gross proceeds are expected to be $4.2 million, prior to deducting underwriting discounts and offering expenses. 10/28/2024

Unlock

PLRZ Ratings Summary

PLRZ Quant Ranking

What is Polyrizon Ltd.'s stock price?

Is Polyrizon Ltd. (PLRZ) overvalued or undervalued?

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

Polyrizon Announces Closing of $4.2 Million Initial Public Offering

Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”